Navigation Links
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
Date:7/14/2009

d by low levels or absence of a protein called a clotting factor, essential for blood clotting. This inability to clot results from an error in a person's genetic code, and occurs in approximately 1 in 10,000 male births. It is estimated that over 400,000 people worldwide suffer from hemophilia, of which only 25% currently receive therapy. It is estimated that the market for hemophilia treatment is in excess of seven billion dollars annually. There are two types of hemophilia, hemophilia A and hemophilia B. Hemophilia A is caused by a lack of Factor VIII and hemophilia B is caused by a deficiency of Factor IX.

About Inspiration Biopharmaceuticals

Inspiration Biopharmaceuticals was founded in 2004 with the mission to revolutionize treatments for hemophilia. The Company is focused on developing products that have the potential to broaden patient access to therapy, including prophylactic use. Greater access and more frequent prophylactic therapy have been shown to reduce complications of the disease and enhance patients' long-term health and quality of life.

Underlying the Company's programs is a novel, proprietary manufacturing technology that allows a greater yield of high-quality protein. Inspiration is utilizing this technology to develop a portfolio of hemophilia and bleeding disorder products that address a $7 billion market worldwide. Inspiration's lead product candidate IB1001, an intravenous recombinant Factor IX, has completed preclinical testing and is now being evaluated in a Phase 1/2-3 clinical study in the United States and Israel and is poised to enter clinical testing in Europe.


'/>"/>
SOURCE Inspiration Biopharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Positive results from Pyratine XR(TM) rosacea-specific study also slated ... March 8, 2009 - NAPA, Calif., March 5 ... sciences company engaged in the development of technologies that ... Pyratine XR(TM) is officially launching at the American Academy ...
... the launch of a suite of miRNA functional ... vector based precursor miRNA expression clones; 2) miTarget(TM) ... 3) All-in-One(TM) miRNA RT-qPCR system.Constructed in a lentiviral ... collections cover all known miRNAs for human ...
... 5 Poniard Pharmaceuticals, Inc. (Nasdaq: ... oncology therapies, today announced that it will hold ... quarter and year-end financial results and provide a ... the Company,s lead product candidate.Jerry McMahon, Ph.D., chairman ...
Cached Biology Technology:Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 2Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 3GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools 2Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12 2
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... International Liver CongressTM 2013 has demonstrated the, accuracy of ... Non Alcoholic Fatty Liver disease (NAFLD) comprises two ... relatively benign and one group with NASH which may ... the only means of distinguishing the two was to ...
... 23, 2013  Aware, Inc. (NASDAQ: AWRE ), a ... assurance software products, today reported financial results for its first ... the first quarter of 2013 was $5.6 million, an increase ... last year. Operating income before patent related income in the ...
... April 23, 2013 Governor Tom Corbett ... with its 2013 BIO Governor of the Year Award in ... and public health sectors within Pennsylvania . ... BIO International Convention in Chicago, Ill. ...
Cached Biology News:Aware, Inc. Reports First Quarter 2013 Financial Results 2Aware, Inc. Reports First Quarter 2013 Financial Results 3Aware, Inc. Reports First Quarter 2013 Financial Results 4Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award 2Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award 3
... Mutation Explorer processes up to 48 ... traces. Data input can be from either ... terminator or primer chemistries. The detection parameters ... analyst to analyst consistency. We have ...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
... XL provides balance data collection and automation that ... integration with Microsoft Excel , Pre-configured library ... , New balances can be added and configured ... from multiple balances into one spreadsheet ...
Biology Products: